ACRS [NASD]
Aclaris Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.29 Insider Own0.30% Shs Outstand66.67M Perf Week-5.08%
Market Cap1.12B Forward P/E- EPS next Y-1.67 Insider Trans-52.55% Shs Float60.26M Perf Month9.62%
Income-82.10M PEG- EPS next Q-0.45 Inst Own96.60% Short Float / Ratio5.35% / 9.14 Perf Quarter-2.80%
Sales23.50M P/S47.86 EPS this Y-33.20% Inst Trans0.47% Short Interest3.22M Perf Half Y12.74%
Book/sh3.30 P/B5.04 EPS next Y-19.30% ROA-32.10% Target Price34.33 Perf Year31.13%
Cash/sh3.67 P/C4.53 EPS next 5Y- ROE-39.40% 52W Range9.26 - 18.96 Perf YTD14.44%
Dividend- P/FCF- EPS past 5Y6.50% ROI-45.50% 52W High-12.23% Beta0.59
Dividend %- Quick Ratio13.00 Sales past 5Y- Gross Margin50.70% 52W Low79.70% ATR1.01
Employees75 Current Ratio13.00 Sales Q/Q1046.40% Oper. Margin- RSI (14)50.06 Volatility7.04% 5.82%
OptionableYes Debt/Eq0.00 EPS Q/Q13.40% Profit Margin- Rel Volume1.23 Prev Close15.86
ShortableYes LT Debt/Eq0.00 EarningsNov 08 BMO Payout- Avg Volume352.69K Price16.64
Recom1.40 SMA20-1.34% SMA503.56% SMA2008.53% Volume435,117 Change4.92%
Dec-01-22Initiated Goldman Buy $25
Oct-06-22Initiated BTIG Research Buy $32
Jul-23-21Resumed Jefferies Buy $27 → $32
Jun-15-21Initiated Piper Sandler Overweight $30
Apr-21-21Initiated H.C. Wainwright Buy $40
Oct-22-19Upgrade SVB Leerink Mkt Perform → Outperform
Sep-06-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-27-19Downgrade SVB Leerink Outperform → Mkt Perform
May-06-19Initiated SVB Leerink Outperform $13
Mar-28-18Resumed Leerink Partners Outperform $52
Show Previous Ratings
Nov-29-22 07:00AM
Nov-26-22 01:39PM
Nov-22-22 04:01PM
Nov-16-22 12:10PM
Nov-10-22 04:01PM
08:25AM Loading…
Nov-08-22 08:25AM
07:00AM
Oct-26-22 06:44AM
Sep-27-22 07:00AM
Sep-15-22 06:46AM
Aug-30-22 07:00AM
Aug-25-22 07:00AM
Aug-05-22 07:59AM
Aug-03-22 08:25AM
07:00AM
07:00AM Loading…
Aug-01-22 07:00AM
Jul-15-22 12:00PM
Jul-08-22 09:40AM
Jul-01-22 09:36AM
Jun-27-22 07:00AM
Jun-22-22 09:40AM
Jun-20-22 08:20AM
Jun-13-22 09:55AM
Jun-06-22 09:40AM
Jun-01-22 04:01PM
May-27-22 09:55AM
May-17-22 11:53AM
May-16-22 07:00AM
May-10-22 08:15AM
07:00AM
07:35PM Loading…
May-04-22 07:35PM
May-03-22 07:00AM
May-02-22 06:10AM
Apr-13-22 12:17AM
Feb-24-22 08:55AM
07:00AM
Feb-21-22 04:34AM
Feb-17-22 03:03PM
Feb-06-22 04:33PM
Feb-02-22 07:00AM
Feb-01-22 04:01PM
Jan-11-22 04:01PM
Dec-27-21 07:00AM
Dec-20-21 05:21PM
Dec-08-21 11:59AM
Dec-03-21 07:00AM
Nov-23-21 04:13AM
Nov-18-21 04:01PM
Nov-03-21 07:00AM
Nov-02-21 08:25AM
07:00AM
Oct-27-21 03:03PM
Oct-12-21 07:16PM
Sep-29-21 08:47AM
Sep-20-21 08:00AM
Aug-26-21 04:01PM
Aug-25-21 06:16AM
Aug-05-21 10:58AM
07:00AM
Jul-30-21 03:00PM
Jul-08-21 07:00AM
Jul-06-21 11:49AM
10:13AM
Jun-09-21 07:55PM
11:00AM
Jun-08-21 04:15PM
07:46AM
07:00AM
May-18-21 01:25AM
May-17-21 07:00AM
May-07-21 08:35AM
07:00AM
Apr-29-21 05:02PM
Apr-26-21 01:39AM
Mar-15-21 07:00AM
Feb-25-21 07:00AM
Feb-22-21 07:00AM
Feb-10-21 07:00AM
Jan-25-21 02:40PM
Jan-20-21 01:25PM
12:13PM
10:30AM
08:45AM
07:32AM
04:19AM
Jan-19-21 04:34PM
04:01PM
12:10PM
07:00AM
Dec-28-20 11:17PM
Dec-23-20 09:11AM
Dec-15-20 11:26PM
07:00AM
Nov-16-20 04:01PM
Nov-14-20 07:08AM
Nov-06-20 12:00PM
Nov-04-20 08:25AM
07:00AM
Oct-29-20 12:35PM
Oct-21-20 10:46AM
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCHIFF ANDREW NDirectorNov 14Sale17.081,37123,417434,455Nov 14 04:51 PM
SCHIFF ANDREW NDirectorNov 11Sale17.0641,160702,177435,826Nov 14 04:51 PM
SCHIFF ANDREW NDirectorNov 10Sale17.0211,395193,995476,986Nov 14 04:51 PM
SCHIFF ANDREW NDirectorOct 26Sale17.0014,540247,253488,381Oct 26 07:09 PM
SCHIFF ANDREW NDirectorOct 25Sale17.0212,018204,516502,921Oct 26 07:09 PM
SCHIFF ANDREW NDirectorOct 24Sale17.0114,616248,586514,939Oct 26 07:09 PM
SCHIFF ANDREW NDirectorOct 18Sale16.8932,093542,022529,555Oct 19 04:49 PM
SCHIFF ANDREW NDirectorOct 17Sale16.0519,944320,087561,648Oct 19 04:49 PM
Monahan JosephChief Scientific OfficerOct 17Sale15.985,00079,908101,386Oct 19 04:45 PM
SCHIFF ANDREW NDirectorOct 07Sale16.167,324118,349581,592Oct 11 04:35 PM
SCHIFF ANDREW NDirectorOct 06Sale16.5437,839625,744588,916Oct 06 05:58 PM
SCHIFF ANDREW NDirectorOct 04Sale16.017,700123,259626,755Oct 06 05:58 PM
SCHIFF ANDREW NDirectorJun 17Sale15.1419,565296,2690Jun 21 04:57 PM
Walker NealPresident and CEOApr 25Sale15.1820,000303,6561,245,763Apr 25 05:13 PM
Walker NealPresident and CEOApr 22Sale15.0425,000376,0981,265,763Apr 25 05:13 PM
Walker NealPresident and CEOApr 21Sale15.2425,000380,9481,290,763Apr 25 05:13 PM
Monahan JosephChief Scientific OfficerApr 18Sale16.2830,000488,298106,386Apr 20 05:06 PM
Walker NealPresident and CEOMar 11Sale15.9156,303896,0451,315,763Mar 14 04:58 PM
Ruffo FrankChief Financial OfficerMar 10Sale15.5512,823199,335201,883Mar 14 04:56 PM
Monahan JosephChief Scientific OfficerMar 10Sale15.7127,165426,803136,386Mar 14 04:53 PM
Monahan JosephChief Scientific OfficerFeb 09Sale12.683834,85787,301Feb 11 04:22 PM